COMPASS Pathways plc (CMPS)

Market Cap	1.28B +126.9%
Revenue (ttm)	n/a
Net Income	-266.30M
EPS	-2.22
Shares Out	141.71M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,645,091
Open	9.01
Previous Close	9.12
Day's Range	8.53 - 9.16
52-Week Range	4.88 - 15.87
Beta	2.41
Analysts	Strong Buy
Price Target	23.31 (+158.71%)
Earnings Date	Nov 3, 2026

About CMPS

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in L...

• Industry: Medical Care Facilities
• Sector: Healthcare
• IPO Date: Sep 18, 2020
• Employees: 156
• Stock Exchange: Nasdaq
• Ticker Symbol: CMPS
• Website: https://compasspathways.com

Analyst Summary

According to 16 analysts, the average rating for CMPS stock is "Strong Buy." The 12-month stock price target is $23.31, which is an increase of 158.71% from the latest price.

Price Target

$23.31

(158.71% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Nov 14, 2026

Data Sources Report a data error